Formycon AG (FYB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Formycon AG (FYB) has a cash flow conversion efficiency ratio of 0.011x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€4.54 Million ≈ $5.30 Million USD) by net assets (€399.14 Million ≈ $466.63 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Formycon AG (FYB) net asset quality to measure how much of total assets are equity-financed.
Formycon AG - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Formycon AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Formycon AG to evaluate the quality of earnings relative to operating cash generation.
Formycon AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Formycon AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ratos AB (publ)
ST:RATO-A
|
0.001x |
|
Fagerhult AB
ST:FAG
|
0.049x |
|
Shenzhen King Brother Electronics Technology Co.Ltd.
SHE:301041
|
N/A |
|
Ascencio (D)
BR:ASCE
|
0.035x |
|
Palisade Bio Inc
NASDAQ:PALI
|
-0.031x |
|
Regal Asian Investments Ltd
AU:RG8
|
N/A |
|
BRASI.CIA BRAS.D.PROP.ADR
F:52BA
|
-0.017x |
|
Alucon Public Company Limited
BK:ALUCON
|
0.018x |
Annual Cash Flow Conversion Efficiency for Formycon AG (2009–2025)
The table below shows the annual cash flow conversion efficiency of Formycon AG from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see FYB company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €399.14 Million ≈ $466.63 Million |
€10.78 Million ≈ $12.61 Million |
0.027x | +153.73% |
| 2024-12-31 | €461.84 Million ≈ $539.94 Million |
€-23.22 Million ≈ $-27.15 Million |
-0.050x | -156.68% |
| 2023-12-31 | €502.75 Million ≈ $587.77 Million |
€-9.85 Million ≈ $-11.51 Million |
-0.020x | +63.23% |
| 2022-12-31 | €356.58 Million ≈ $416.88 Million |
€-18.99 Million ≈ $-22.21 Million |
-0.053x | +78.01% |
| 2021-12-31 | €55.89 Million ≈ $65.34 Million |
€-13.54 Million ≈ $-15.83 Million |
-0.242x | -216.50% |
| 2020-12-31 | €68.04 Million ≈ $79.54 Million |
€-5.21 Million ≈ $-6.09 Million |
-0.077x | -145.04% |
| 2019-12-31 | €48.21 Million ≈ $56.36 Million |
€-1.51 Million ≈ $-1.76 Million |
-0.031x | -107.81% |
| 2018-12-31 | €33.24 Million ≈ $38.86 Million |
€13.30 Million ≈ $15.55 Million |
0.400x | +345.01% |
| 2017-12-31 | €25.54 Million ≈ $29.86 Million |
€-4.17 Million ≈ $-4.88 Million |
-0.163x | +32.29% |
| 2016-12-31 | €20.89 Million ≈ $24.42 Million |
€-5.04 Million ≈ $-5.89 Million |
-0.241x | -1260.19% |
| 2015-12-31 | €24.87 Million ≈ $29.08 Million |
€517.00K ≈ $604.43K |
0.021x | +981.57% |
| 2014-12-31 | €13.64 Million ≈ $15.95 Million |
€-32.17K ≈ $-37.61K |
-0.002x | +99.83% |
| 2013-12-31 | €12.25 Million ≈ $14.32 Million |
€-16.65 Million ≈ $-19.47 Million |
-1.359x | -368.19% |
| 2012-12-31 | €4.26 Million ≈ $4.98 Million |
€2.16 Million ≈ $2.52 Million |
0.507x | +6644.70% |
| 2011-12-31 | €5.14 Million ≈ $6.01 Million |
€38.60K ≈ $45.13K |
0.008x | +101.07% |
| 2010-12-31 | €4.07 Million ≈ $4.76 Million |
€-2.85 Million ≈ $-3.33 Million |
-0.700x | +8.21% |
| 2009-12-31 | €640.00K ≈ $748.23K |
€-487.93K ≈ $-570.44K |
-0.762x | -- |
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well… Read more